Faron Pharmaceuticals Oy
LSE: FARN.L0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- London Stock Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Juho Markku Jalkanen
- Employees
- 25
- Headquarters
- Turku, Finland
- IPO year
- 2015
- Market cap
- £47.9M
- Website
- https://www.faron.com
Loading FARN…
Loading profile data…Frequently asked questions about FARN
What does Faron Pharmaceuticals Oy (FARN.L) do?
Faron Pharmaceuticals Oy operates as a clinical stage drug discovery and development company. The company develops a pipeline of immune modulation based proprietary drug candidates for unmet need, including immuno-oncology, and organ protection and regenerative medicine. Its lead product candidates are Traumakine, an intravenous interferon beta-...
Where does FARN.L trade?
Faron Pharmaceuticals Oy (FARN.L) trades on the London Stock Exchange.
What sector is FARN.L in?
Faron Pharmaceuticals Oy (FARN.L) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Faron Pharmaceuticals Oy?
Juho Markku Jalkanen is the chief executive officer of Faron Pharmaceuticals Oy (FARN.L).
Where is Faron Pharmaceuticals Oy headquartered?
Faron Pharmaceuticals Oy is headquartered in Finland.
Does FARN.L pay a dividend?
Faron Pharmaceuticals Oy (FARN.L) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did FARN.L go public?
Faron Pharmaceuticals Oy (FARN.L) completed its initial public offering in 2015.